Ozempic may do more than shrink waistlines — it could slow aging itself

GLP-1 drugs like Ozempic and Wegovy are already celebrated for weight loss, blood sugar control, and heart health. Now, two new studies suggest they may also be tapping into something far more fundamental: the biology of aging itself.

In a NIH-funded study from UC Berkeley, researchers gave semaglutide to 20-month-old female mice for three months. The treated mice showed better memory, stronger muscles, reduced inflammation, and improved tissue repair — and those given the drug until death lived nearly 100 days longer than untreated mice. Crucially, semaglutide outperformed calorie restriction — long considered the gold standard for longevity research — in several key areas, suggesting it may activate a distinct biological pathway. On the human side, a UC San Diego clinical trial published in Nature Communications found that semaglutide slowed biological aging markers in adults with HIV, the first randomized, placebo-controlled evidence of this effect in people.

By the Numbers:

• ~100 extra days of median lifespan in semaglutide-treated mice vs. untreated controls
• 9% slower pace of biological aging based on the DunedinPACE epigenetic clock (human trial)
• 49% of participants in a related pilot study showed longer telomeres after semaglutide treatment
• 108 adults with HIV enrolled in the human clinical trial

Why it matters: Most chronic diseases are rooted in aging. If GLP-1 drugs genuinely slow that process — even partially — it could reframe how clinicians think about prescribing them, potentially expanding their use well beyond obesity and diabetes to healthy older adults. Larger clinical trials will be needed to confirm whether these effects translate broadly across human populations.